NCT06852950 Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
| NCT ID | NCT06852950 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt University Medical Center |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-03-09 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-03-09 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to improve patient awareness of the utility of continuous glucose monitoring systems in blood glucose monitoring and to improve patient satisfaction regarding diabetes care, particularly in the matter of blood glucose monitoring, at the transitions of care from the inpatient setting to the ambulatory setting.
Eligibility Criteria
Inclusion Criteria: * Non-pregnant adults, ages greater than or equal to 18 years, admitted to VUMC * Able to give informed consent * Hyperglycemia requiring insulin therapy including subcutaneous insulin injection or continuous subcutaneous insulin infusion (patient's own insulin pump) during hospitalization and at the time of discharge * POC glucose or venous glucose levels in the 24 hours prior to participation need to be 70-350 mg/dL * Need glucose readings greater than or equal to one time per day * Mental status and dexterity adequate to use Libre 3 Plus or Dexcom G7 sensors with Libre 3 or Dexcom G7 application on patient's smartphone Exclusion Criteria: * Currently using Libre 3 Plus or Dexcom G7 CGMS during hospitalization or have used Libre 3 Plus or Dexcom G7 CGMS in the past 3 months * Does not have smartphone compatible with Libre 3 App or Dexcom G7 App * Received chemotherapy during current hospitalization * Planning on major surgery within 10-15 days * Hemodialysis or peritoneal dialysis * Requiring vasopressors, intubation, sedation, or admission to an intensive care unit * Vitamin C use of more than 500 milligrams per day * Hydroxyurea use * Acetaminophen use of more than 4 grams per day or 1 gram every 6 hours * Significant pitting edema (3+ or greater) i.e. cirrhosis with ascites, congestive heart failure with edema, nephrotic syndrome, or signs of poor perfusion * Presentation in diabetic ketoacidosis or hyperosmotic nonketotic state * Skin allergy to adhesives
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06852950 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06852950 currently recruiting?
Yes, NCT06852950 is actively recruiting participants. Contact the research team at angel.morvant@vumc.org for enrollment information.
Where is the NCT06852950 trial being conducted?
This trial is being conducted at Nashville, United States.
Who is sponsoring the NCT06852950 clinical trial?
NCT06852950 is sponsored by Vanderbilt University Medical Center. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.